View Older Stories View More Recent Stories
-
After-hours movers: HPE, Ulta Beauty, SoFi, Rubrik and more
-
Praxis stops EMBOLD study early after relutrigine shows efficacy
-
Praxis receives FDA alignment on ulixacaltamide NDA submission plans
-
TD Cowen on Praxis Precision Medicines Inc. (PRAX): 'Sensitivity Analyses Robust & Supportive Of Topline'
-
Praxis Precision Medicines (PRAX) Mentioned as Short at Culper Research
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $540 at Guggenheim
-
Praxis Precision Medicines (PRAX) Tops Q3 EPS by 11c
-
Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $250 at Oppenheimer
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $360 at Truist Securities
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $275 at Baird
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $251 at TD Cowen as Ph3 ET Ulixa Studies Meet Primary
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $350 at Guggenheim
-
Piper Sandler Sees a 'Lucrative Buying Opportunity Ahead' for Praxis Precision Medicines (PRAX)
-
Jones Trading Starts Praxis Precision Medicines Inc. (PRAX) at Buy
-
Piper Sandler Reiterates Overweight Rating on Praxis Precision Medicines Inc. (PRAX)
-
Piper Sandler Reiterates OW Rating on Praxis Precision Medicines Inc. (PRAX)
-
Truist Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $115 at H.C. Wainwright
-
TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $33 at Wedbush
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $155 at Guggenheim
-
Praxis Precision Medicines (PRAX) Misses Q2 EPS by 6c
-
Praxis reports positive seizure reduction results from vormatrigine trial
-
H.C. Wainwright Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis receives FDA breakthrough therapy designation for relutrigine
-
Piper Sandler Reiterates OW Rating on Praxis Precision Medicines (PRAX) Post NYC Investor Dinner
-
Oppenheimer Assumes Praxis Precision Medicines Inc. (PRAX) at Outperform
-
Piper Sandler: 'We Remain Bullish on Praxis Precision Medicines Inc. (PRAX)'
-
Chardan Capital Markets Starts Praxis Precision Medicines Inc. (PRAX) at Buy
-
Praxis Precision Medicines (PRAX) Highlights DEE Clinical Program Updates at Virtual Investor Event
-
Guggenheim on Praxis Precision Medicines Inc. (PRAX): 'remains one of our Top Picks for 2025'
-
Praxis Precision Medicines (PRAX) Misses Q1 EPS by 42c
-
Praxis Precision Medicines (PRAX) announces inducement grants
-
Praxis Precision Medicines Inc. (PRAX) PT Lowered to $61 at TD Cowen
-
Praxis Precision Medicines Inc. (PRAX) PT Lowered to $85 at Truist Securities
-
Praxis Precision Medicines (PRAX) IDMC has recommended Essential3 study be stopped for futility
-
Deutsche Bank Starts Praxis Precision Medicines Inc. (PRAX) at Buy
-
Jefferies Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $175 at Truist; 'Incrementally Positive On Ph3 ESSENTIAL3'
-
Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
Praxis Precision Medicines (PRAX) Files Mixed Shelf
-
Piper Sandler on Praxis Precision Medicines Inc. (PRAX): '2025 a Key Year to Drive Substantial Shares Gains'
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $305 at Jefferies
-
Piper Sandler Reiterates Overweight Rating on Praxis Precision Medicines Inc. (PRAX)
-
Guggenheim Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis Precision Medicines (PRAX) Misses Q3 EPS by 76c
-
Oppenheimer Reiterates Outperform Rating on Praxis Precision Medicines Inc. (PRAX)
-
Piper Sandler Reiterates Overweight Rating on Praxis Precision Medicines Inc. (PRAX)

